Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus

PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.

Zacks Investment Research • Feb 20, 2026

Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript

Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 20, 2026

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights.

Business Wire • Feb 19, 2026

Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates

Prothena (PRTA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $1.08 per share a year ago.

Zacks Investment Research • Feb 19, 2026

Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?

PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.

Zacks Investment Research • Feb 16, 2026

FTRE vs. PRTA: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Feb 13, 2026

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that it will report its fourth quarter and full year 2025 financial results on Thursday 2/19/26 with a conference call at 4:30pm ET.

Business Wire • Feb 12, 2026

All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy

Prothena (PRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Jan 21, 2026

Prothena Announces Board of Directors Update

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company's vision and strategy. “I would like to than.

Business Wire • Dec 12, 2025

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025.

Business Wire • Nov 19, 2025